Onkologie. 2023:17(3):188-191 | DOI: 10.36290/xon.2023.037

Rechallenge with anti-EGFR therapy

Marián Liberko, Renata Soumarová
Onkologická klinika a 3. lékařská fakulta Univerzity Karlovy FNKV, Praha

Continuum of care is a concept of treatment in which periods of aggressive, induction chemotherapy are followed by maintenance treatment with the aim to prolong overall survival of mCRC patients. Rechallenge with anti-EGFR drugs is a part of this concept. With this strategy, we may achieve significant response and control of disease, even in later lines of treatment, in selected group of patients. The aim of this review is to provide an overview of rechallenge with anti-EGFR therapy in the treatment of mCRC.

Keywords: metastatic colorectal cancer, rechallenge, anti-EGFR treatment.

Accepted: June 12, 2023; Published: June 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. Rechallenge with anti-EGFR therapy. Onkologie. 2023;17(3):188-191. doi: 10.36290/xon.2023.037.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233-254. doi: 10.3322/caac.21772. Epub 2023 Mar 1. PMID: 36856579. Go to original source... Go to PubMed...
    2. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32. doi: 10.1016/j.annonc.2022.10.003. Epub 2022 Oct 25. PMID: 36307056. Go to original source... Go to PubMed...
    3. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713-1729. doi: 10.1093/annonc/mdx175. PMID: 28407110; PMCID: PMC6246616. Go to original source... Go to PubMed...
    4. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. PMID: 31566309. Go to original source... Go to PubMed...
    5. André T, Shiu KK, Kim TW, et al. KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020;383(23):2207-2218. doi: 10.1056/NEJMoa2017699. PMID: 33264544 Go to original source... Go to PubMed...
    6. André T, Lonardi S, Wong KYM, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022;33(10):1052-1060. doi: 10.1016/j.annonc.2022.06.008. Epub 2022 Jun 25. PMID: 35764271. Go to original source... Go to PubMed...
    7. Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795-801. doi: 10.1038/nm.3870. Epub 2015 Jun 1. Erratum in: Nat Med. 2015 Jul;21(7):doi:10.1038/nm0715-827b. Erratum in: Nat Med. 2015;21(7):827. PMID: 26030179; PMCID: PMC4868598. Go to original source... Go to PubMed...
    8. Parseghian CM, Sun R, Woods M, et al. Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol. 2023;41(3):460-471. doi: 10.1200/JCO.22.01423. Epub 2022 Nov 9. PMID: 36351210; PMCID: PMC9870238. Go to original source... Go to PubMed...
    9. Vidal J, Muinelo L, Dalmases A, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. 2017;28(6):1325-1332. doi: 10.1093/annonc/mdx125. PMID: 28419195; PMCID: PMC5834035. Go to original source... Go to PubMed...
    10. Parseghian CM, Loree JM, Morris VK, et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019;30(2):243-249. doi: 10.1093/annonc/mdy509. PMID: 30462160; PMCID: PMC6657008. Go to original source... Go to PubMed...
    11. Morelli MP, Overman MJ, Dasari A, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26(4):731-736. doi: 10.1093/annonc/mdv005. Epub 2015 Jan 26. PMID: 25628445; PMCID: PMC4374387. Go to original source... Go to PubMed...
    12. Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23(9):2313-2318. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5. Erratum in: Ann Oncol. 2017;28(11):2906. PMID: 22396447. Go to original source... Go to PubMed...
    13. Cremolini C, Rossini D, Dell'Aquila E, et al. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. JAMA Oncol. 2019;5(3):343-350. doi: 10.1001/jamaoncol.2018.5080. PMID: 30476968; PMCID: PMC6439839. Go to original source... Go to PubMed...
    14. Sunakawa Y, Nakamura M, Ishizaki M, et al. RASMutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer. JCO Precis Oncol. 2020;4:898-911. doi: 10.1200/PO.20.00109. PMID: 35050760 Go to original source... Go to PubMed...
    15. Masuishi T, Tsuji A, Kotaka M, et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br J Cancer. 2020;123(10):1490-1495. doi: 10.1038/s41416-020-01042-w. Epub 2020 Aug 31. PMID: 32863385; PMCID: PMC7652864. Go to original source... Go to PubMed...
    16. Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612-1618. doi: 10.1038/s41591-022-01886-0. Epub 2022 Aug 1. PMID: 35915157; PMCID: PMC9386661. Go to original source... Go to PubMed...
    17. Ferris RL, Lenz HJ, Trotta AM, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018;63:48-60. doi: 10.1016/j.ctrv.2017.11.008. Epub 2017 Dec 2. PMID: 29223828; PMCID: PMC7505164. Go to original source... Go to PubMed...
    18. Martinelli E, Martini G, Famiglietti V, et al. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA Oncol. 2021;7(10):1529-1535. doi: 10.1001/jamaoncol.2021.2915. PMID: 34382998; PMCID: PMC8531995. Go to original source... Go to PubMed...
    19. Napolitano S, Martini G, Ciardiello D, et al. CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. Front Oncol. 2022;12:940523. doi: 10.3389/fonc.2022.940523. PMID: 35832541; PMCID: PMC9272566. Go to original source... Go to PubMed...
    20. Rossini D, Germani MM, Pagani F, et al. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. Clin Colorectal Cancer. 2020;19(3):191-199.e6. doi: 10.1016/j.clcc.2020.03.009. Epub 2020 Apr 11. PMID: 32466976. Go to original source... Go to PubMed...
    21. Ciardiello D, Napolitano S, Famiglietti V, et al. Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials. Cancers (Basel). 2023;15(7):2117. doi: 10.3390/cancers15072117. PMID: 37046778; PMCID: PMC10093522. Go to original source... Go to PubMed...
    22. Sawa H, Shinozaki E, Nakamura M, et al. Phase II study of cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer: E-rechallenge trial. Ann Oncol. 2018;29(suppl 8):viii161. doi: 10.1093/annonc/mdy281.029. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.